> Details

Yan, Michael; Li, Zhihao; Muñoz-Schuffenegger, Pablo; Santiago, Anna; Claasen, Marco; Bucur, Roxana; McGilvray, Ian M.; Moulton, Carol-Anne; Reichman, Trevor; Shwaartz, Chaya; Cleary, Sean P.; O'Kane, Grainne M.; Grant, Robert C; Kim, Tae; Naidoo, Catherine Soo Yee; Hosni, Ali; Wong, Rebecca KS; Mesci, Aruz; Sapisochin, Gonzalo; Dawson, Laura A.

Comparing resection and stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion: A propensity score matched study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Comparing resection and stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion: A propensity score matched study
  • Contributor: Yan, Michael; Li, Zhihao; Muñoz-Schuffenegger, Pablo; Santiago, Anna; Claasen, Marco; Bucur, Roxana; McGilvray, Ian M.; Moulton, Carol-Anne; Reichman, Trevor; Shwaartz, Chaya; Cleary, Sean P.; O'Kane, Grainne M.; Grant, Robert C; Kim, Tae; Naidoo, Catherine Soo Yee; Hosni, Ali; Wong, Rebecca KS; Mesci, Aruz; Sapisochin, Gonzalo; Dawson, Laura A.
  • Published: American Society of Clinical Oncology (ASCO), 2024
  • Published in: Journal of Clinical Oncology, 42 (2024) 3_suppl, Seite 521-521
  • Language: English
  • DOI: 10.1200/jco.2024.42.3_suppl.521
  • ISSN: 0732-183X; 1527-7755
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: 521 Background: Macrovascular invasion (MVI) in hepatocellular carcinoma (HCC) patients is a poor prognostic factor. Current guidelines endorse systemic therapy for MVI. Local therapies present a potential for obliteration of MVI and improved survival. Surgery has been the standard local therapy at our institution, and stereotactic body radiotherapy (SBRT) has emerged as an alternative local therapy for this patient population. Methods: In this retrospective study, one-to-one optimal pair propensity score matching was used to compare outcomes of HCC patients with MVI who underwent surgery or received SBRT. Matching was done based on sex, age, ECOG, cirrhosis presence, Child-Pugh class, number of tumours, tumour volume, alpha-fetoprotein level, ALBI score, Japanese Classification of portal vein invasion, and hepatic vein invasion. Overall survival was estimated using the Kaplan-Meier method and between group differences determined using the log-rank test. The cumulative incidence of recurrence, accounting for the competing risk of death, was compared using Gray’s test. Results: Ninety of 193 patients were included after matching (45 patients in both the surgery and SBRT groups) (Table). The SBRT group had a median OS of 15 months (95% CI: 10-38), while in the surgery group it was 24 months (95% CI: 11-81). Comparing the 12-, 36-, and 60-month overall survival (OS) rates between the SBRT group (57%, 33%, 15%) and the surgery group (58%, 37%, 34%), there was no statistically significant differences (p=0.16); the 5-year OS was double in the surgical resection group. The 12-, 36-, and 60-month cumulative incidence of HCC recurrence in the SBRT group (47%, 73%, 75%) was comparable to the surgery group (69%, 69%, 69%) (p=0.89). Conclusions: Long term survival is possible in patients with HCC and MVI in a substantial minority of patients with HCC and MVI treated with local therapies. There was no statistical difference in outcomes; however, surgical resection resulted in numerically longer survival outcomes compared to SBRT after propensity score adjustment. There is rationale for investigating both local therapies with systemic therapies in future clinical trials. [Table: see text]